The hematopoietic stem cell transplantation (HSCT) market involves transplanting stem cells to replace damaged or destroyed bone marrow. HSCT is a well-established treatment option for various blood cancers including leukemia, lymphoma and myeloma. It can also be used for some genetic, metabolic, and immune disorders of the blood.
The global HSCT market is estimated to be valued at US$ 3.57 Bn in 2024 and is expected to exhibit a CAGR of 11 % over the forecast period 2024 To 2031.
Key players operating in the HSCT market include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., copyright Inc., Sanofi, FUJIFILM Holdings Corporation.
Key players operating in the Hematopoietic Stem Cell Transplantation Market Size such as Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc. are developing innovative therapies for hematopoietic stem cell transplantation. Advancement in stem cell therapy and development of third-party stem cell banks are providing key opportunities in this market.
The global HSCT market is witnessing expansion owing to rising blood cancer incidence worldwide. Increasing research for developing novel transplantation methods, growth of stem cell therapy and rising investment in cell and gene therapy are supporting the market growth.
The rising prevalence of blood cancers such as leukemia, lymphoma and myeloma is a major market driver. Blood cancers prevalence is increasing globally due to lifestyle changes and increasing environmental pollution. As HSCT is a well-established treatment for these cancers, increasing patient pool will drive the demand for HSCT procedures over the forecast period.
PEST Analysis
Political: The government regulations regarding HSCT procedures and clinical trials has a significant impact. The regulations encourages more research in this area.
Economic: Growing healthcare spending and increasing adoption of advanced treatment procedures is fueling the market growth. The high cost associated with HSCT procedures can limit the market.
Social: Increasing awareness about HSCT and advanced treatment options for blood cancers and genetic disorders is driving more patients to undergo such procedures.
Technological: Advancements in stem cell therapies, availability of clinical trial data, development of improved transplantation techniques and standardization of protocols is supporting the market growth. Increased R&D is helping in developing newer treatment options.
The North America region dominates the hematopoietic stem cell transplantation market in terms of value owing to presence of advanced healthcare facilities, favorable reimbursement policies, increasing adoption of stem cell therapies for treatment of chronic diseases. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to growing geriatric population, rising healthcare spending, increasing incidences of hematological malignancies and genetic disorders.
Europe also captures significant share in the global hematopoietic stem cell transplantation market due to well-developed healthcare infrastructure, strong government support for research activities and presence of leadin. copyright in North America dominates the market in terms of value due to presence of advanced medical facilities, favorable reimbursement policies and high treatment cost.
Get More Insights on- Hematopoietic Stem Cell Transplantation Market
For Deeper Insights, Find the Report in the Language that You want:
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments on “Hematopoietic stem cell transplantation (HSCT) Market estimated to witness high growth owing to rising prevalence of blood cancer”